Have to quickly see who can do what in eRA Commons? Check out these handy guides for both at a glance and detailed information on the roles and privileges of eRA Commons users. Continue reading
A new resource, RPPRs: Who Can Do What? provides a quick look at the Annual, Interim, and Final Research Performance Progress Reports (RPPRs), including information such as due dates and how to access RPPR links. It also charts what happens to the Interim RPPR when a Type 2, Competing Renewal application is submitted. Continue reading
We recently released a policy notice announcing that as of September 26, 2018, the NIH will no longer be offering the Protecting Human Research Participants (PHRP) course. It is important to note that investigators are still required to comply with all aspects of the NIH policy Required Education in the Protection of Human Research Participants, and can do so through a different training program or course.
Continue reading
On Friday, Sept. 14, General Registration Rates end for this valuable and unique learning opportunity, designed for those new to working with the NIH grants process. If you are interested in attending the Fall NIH Regional Seminar in San Francisco, CA (Oct. 17-19) and have not registered yet, then now is the time! Continue reading
Informed consent is a critical component of clinical research, but there are often challenges to making the process meaningful and effective. Explore these challenges with experts from diverse perspectives and learn innovative ways to address them at the “Meeting New Challenges in Informed Consent” installment of HHS Office for Human Research Protections (OHRP) Exploratory Workshop, a new initiative to provide a forum for the research community to exchange ideas on important issues related to human subjects protections.The workshop will include discussion on how to lay the groundwork for meaningful informed consent, effectively present information for high-quality decision making, and more! Continue reading
For decades, NIH has required valid analysis, also known as stratified analysis, to explore how well interventions work across sex/gender and race/ethnicity for all applicable clinical trials. After revising the policy last year, NIH now requires the findings from these stratified analyses to be reported on ClinicalTrials.gov after an applicable NIH-Defined Phase III clinical trial has completed. Wondering about how this impacts your research? Continue reading
Starting January 29, 2019, NIH will begin implementing the Inclusion Across the Lifespan policy, which requires the consideration of age, along with sex/gender and race/ethnicity, in applications that involve human participants. What does this policy mean for you and your study? Continue reading
Are you submitting a K application? Check out some new frequently asked questions (FAQs). Continue reading
It depends. Yes; if the ancillary study adds an additional prospectively assigned intervention to patients or a sub-population of patients within the larger clinical trial and all elements of the NIH clinical trial definition are met. No; if the ancillary study is only adding additional measures to an existing clinical trial. Continue reading
The Glossary of NIH terms now contains definitions for Ancillary Study, Child, Clinical Trial Research Experience, Independent Clinical Trial, and Older Adult. Continue reading